ClinicalTrials.gg
TerminatedNCT01703260Updated Feb 1, 2017Results posted

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

A Phase 2 interventional study of Roflumilast and Pioglitazone in Nonalcoholic Steatohapatitis, sponsored by AstraZeneca. Terminated at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-01.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
Company decision; No safety or efficacy concerns (see detailed description)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of roflumilast and pioglitazone therapy on serum transaminase (ALT) levels in adults with Nonalcoholic SteatoHepatitis.

Read the detailed description

This proof of concept study will evaluate the effect of roflumilast and pioglitazone on transaminase levels and liver fat content.

Takeda has chosen not to continue this Study, however, randomized subjects were allowed to complete the study per protocol.

The decision to terminate the study is not related to any safety concerns with either of the study medications.

02

Conditions studied

  • Nonalcoholic Steatohapatitis

Keywords

  • Drug therapy
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the patient is capable of understanding and complying with protocol requirements.
  2. The patient or, when applicable, the patient's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a historical diagnosis of NASH, established no more than 12 months prior to study entry based on histology (liver ).
  4. Has a NAFLD Activity Score (NAS) of ≥3, with a score of at least 1 in steatosis and lobular inflammation - the subcomponents of NAS. It is acceptable if the score for hepatocyte ballooning is "zero".
  5. The subject has a MRI determined liver fat fraction of equal or higher than 7 percent.
  6. The subject is female or male and aged 18 to 80 years, inclusive.
  7. A male who is nonsterilized and sexually active with a female partner of agrees to use adequate from signing of informed consent throughout the duration of the study and for 30 weeks after last dose.
  8. A female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.
  9. If taking Vitamin E and/or pentoxifylline, the subject has been receiving a stable dose for 6 months prior to randomization, started Vitamin E and/or pentoxifylline therapy prior to the qualifying liver biopsy, and agrees to maintain a stable dose throughout the study when possible.
  10. Subject has an level at Screening between 55 and 250 IU/L, inclusive, and between 60 and 250 IU/L at one other occasion during the 6 months prior to Randomization.
  11. If taking a statin, should be on stable dose for 6 months prior to screening.
  12. If taking angiotensin receptor blockers and fish oil, should be on a stable dose for at least 3 month prior to screening.
  13. If diabetic, the subject is on a stable dose of metformin, dipeptidyl peptidase-4 inhibitor, sulfonylurea or insulin or a combination thereof for at least 3 months prior to Screening.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a history of chronic liver disease other than NASH eg, chronic or acute hepatitis, Wilson's disease, alcoholic liver diseases or any other non-NASH active liver disease.
  2. Subjects with liver cirrhosis (of any cause) or laboratory or clinical signs of functional liver failure
  3. abnormal laboratory values suggesting an undiagnosed disease other than NASH requiring further clinical evaluation (as assessed by the Investigator).
  4. The subject has active cancer or a history of a malignant disease (except basal cell carcinoma) within 5 years prior to Screening or any history of bladder cancer.
  5. Subject with a history of weight loss or weight gain of >10 pounds within 6 months prior to Screening.
  6. Subject with a history of bariatric surgery within 5 years prior to Screening.
  7. The subject has received any compound within 30 days prior to Screening or is currently participating in another clinical study.
  8. The subject has a history of or allergies to roflumilast or pioglitazone including any associated .
  9. The subject is required to take excluded medications.
  10. The subject has taken oral or injectable for longer than 7 days within 3 months prior to Screening.
  11. The subject has poorly controlled Type 1 or Type 2 diabetes mellitus with an ≥8.5 at Screening or per Investigator judgment.
  12. The subject has hepatitis A, B or C.
  13. The subject has severe immunological diseases (eg, known infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy) assessed at Screening.
  14. The subject had a history of diabetic gastroparesis or history of gastric bypass surgery.
  15. The subject had a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
  16. The subject had heart failure of Class (II-IV) regardless of therapy.
  17. The subject had a diastolic blood pressure greater than 100 mm Hg or a systolic blood pressure of greater than 160 mm Hg (The mean of the 3 serial BP measurements will be used to determine subject eligibility).
  18. The subject has presence or history of psychotic disorder that may be associated with suicidal thinking, ideation or behavior. These disorders include, but are not limited to, depression, psychosis, psychotic disorder, and schizophrenia. Subjects will be monitored by Columbia-Suicide Severity Rating Scales throughout the duration of the study.
  19. The subject has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day for women or 3 alcoholic drinks per day for men. One drink is equivalent to a 12-ounce beer, a 4-ounce glass of wine, or a 1-ounce shot of hard liquor.) within 1 year prior to the Screening visit.
  20. The subject has a \<120 g/L for men and \<100 g/L for women.
  21. The subject has received pioglitazone or roflumilast in a previous clinical study or as a therapeutic agent within 1 year prior to screening.
  22. If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  23. The subject is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  24. The subject has significant results from physical examinations or clinical laboratory results that, at the discretion of the investigator, would make it difficult to successfully manage and follow the subject according to the protocol.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Roflumilast + pioglitazone

    Roflumilast dose and pioglitazone dose, orally for up to 4 months

    Drug: Roflumilast · Drug: Pioglitazone

  • Experimental
    Roflumilast

    Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.

    Drug: Roflumilast · Drug: Placebo

  • Experimental
    Pioglitazone

    Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months

    Drug: Pioglitazone · Drug: Placebo

Interventions

  • Roflumilast dose

    Also known as: Daxas, Daliresp

  • Pioglitazone dose

    Also known as: Actos

  • DrugPlacebo

    Pioglitazone placebo-matching dose

  • DrugPlacebo

    Roflumilast placebo-matching dose

06

What researchers measure

Primary outcomes

  1. Amount of Serum Alanine Transaminase (ALT) at Baseline

    Time frame: Baseline

  2. Percent Change From Baseline in Serum ALT at Month 4

    The percent change between the serum ALT value collected at Month 4 or final visit relative to baseline.

    Time frame: Month 4

Secondary outcomes

  1. Amount of Serum Aspartate Transaminase (AST) at Baseline

    Time frame: Baseline

  2. Percent Change From Baseline in Serum AST at Month 4

    The percent change between the serum AST value collected at Month 4 or final visit relative to baseline.

    Time frame: Month 4

  3. Liver Fat Content at Baseline

    Liver fat content was quantitatively measured by evaluating the percentage of proton density fat fraction (PDFF) from an abdominal magnetic resonance imaging (MRI). On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.

    Time frame: Baseline

  4. Change From Baseline in Liver Fat Content at Month 4

    Liver fat content was quantitatively measured by evaluating the percentage of PDFF from an abdominal MRI. On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.

    Time frame: Baseline and Month 4

07

Results

Posted Feb 23, 2016

Participant flow

Participants took part at 11 sites in the United States from 26 April 2013 to 30 September 2014.

Participant flow — Overall Study
MilestoneRoflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Started776
Completed433
Not completed343
Withdrew: Adverse event122
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject001
Withdrew: Study termination120

Outcome measures

PrimaryAmount of Serum Alanine Transaminase (ALT) at Baseline
Time frame:
Baseline
Reported as:
Mean · international units per liter (IU/L)
Amount of Serum Alanine Transaminase (ALT) at Baseline
international units per liter (IU/L)Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Amount of Serum Alanine Transaminase (ALT) at Baseline101.7 ± 56.9883.4 ± 31.63118.8 ± 36.76
PrimaryPercent Change From Baseline in Serum ALT at Month 4

The percent change between the serum ALT value collected at Month 4 or final visit relative to baseline.

Time frame:
Month 4
Reported as:
Mean · percent change
Percent Change From Baseline in Serum ALT at Month 4
percent changeRoflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Percent Change From Baseline in Serum ALT at Month 4-53.89 ± 23.362-56.22 ± 6.014-28.86 ± 53.298
SecondaryAmount of Serum Aspartate Transaminase (AST) at Baseline
Time frame:
Baseline
Reported as:
Mean · IU/L
Amount of Serum Aspartate Transaminase (AST) at Baseline
IU/LRoflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Amount of Serum Aspartate Transaminase (AST) at Baseline64.0 ± 43.4944.9 ± 15.2588.3 ± 73.06
SecondaryPercent Change From Baseline in Serum AST at Month 4

The percent change between the serum AST value collected at Month 4 or final visit relative to baseline.

Time frame:
Month 4
Reported as:
Mean · percent change
Percent Change From Baseline in Serum AST at Month 4
percent changeRoflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Percent Change From Baseline in Serum AST at Month 4-41.31 ± 36.087-43.20 ± 7.339-17.56 ± 45.458
SecondaryLiver Fat Content at Baseline

Liver fat content was quantitatively measured by evaluating the percentage of proton density fat fraction (PDFF) from an abdominal magnetic resonance imaging (MRI). On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.

Time frame:
Baseline
Reported as:
Mean · percentage of PDFF
Liver Fat Content at Baseline
percentage of PDFFRoflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Caudate; (n= 6, 7, 6)22.233 ± 8.275019.107 ± 7.799020.117 ± 9.8492
Left superolateral; (n= 6, 6, 6)19.485 ± 8.808017.813 ± 7.441017.278 ± 7.2225
Left inferolateral; (n= 6, 7, 6)22.385 ± 8.989419.747 ± 7.830619.153 ± 10.5909
Left superomedial: (n= 6, 7, 6)22.115 ± 9.712620.426 ± 7.917020.100 ± 9.8688
Left inferomedial: (n= 6, 6, 6)21.553 ± 9.591218.977 ± 8.697021.530 ± 9.5193
Right anteroinferior: (n= 6, 7, 6)22.478 ± 9.054819.994 ± 9.010320.742 ± 8.7829
Right posteroinferior: (n= 6, 7, 6)23.710 ± 8.647818.804 ± 6.688220.070 ± 9.9727
Right posterosuperior: (n= 6, 7, 6)23.282 ± 9.598418.870 ± 7.576419.943 ± 8.9666
Right anterosuperior: (n=6, 7, 6)23.630 ± 8.745419.786 ± 8.592921.527 ± 9.6648
SecondaryChange From Baseline in Liver Fat Content at Month 4

Liver fat content was quantitatively measured by evaluating the percentage of PDFF from an abdominal MRI. On the basis of Couinaud classification (a classification used to describe functional liver anatomy), the liver was divided into 8 segments: caudate, left superolateral, left inferolateral, left superomedial (4a), left inferomedial (4b), right anteroinferior, right posteroinferior, right posterosuperior and right anterosuperior.

Time frame:
Baseline and Month 4
Reported as:
Mean · percent change in PDFF
Change From Baseline in Liver Fat Content at Month 4
percent change in PDFFRoflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Caudate; (n= 3, 3, 3)-18.787 ± 11.5646-11.590 ± 5.5674-10.287 ± 8.8098
Left superolateral; (n= 6, 6, 6)-15.170 ± 13.7442-10.287 ± 1.9695-8.067 ± 7.6318
Left inferolateral; (n= 3, 3, 3)-14.290 ± 13.1654-10.077 ± 2.9030-8.773 ± 7.0821
Left superomedial: (n= 3, 3, 3)-14.687 ± 13.6909-11.177 ± 3.9429-9.217 ± 8.7999
Left inferomedial: (n= 3, 3, 3)-14.107 ± 15.2957-10.977 ± 5.0052-9.417 ± 8.9360
Right anteroinferior: (n= 3, 3, 3)-13.990 ± 13.1266-10.260 ± 6.9972-7.693 ± 9.7985
Right posteroinferior: (n=3, 3, 3)-18.073 ± 13.1470-9.250 ± 1.6808-8.790 ± 10.2188
Right posterosuperior: (n=3, 3, 3)-17.717 ± 13.0691-9.797 ± 4.4053-8.113 ± 10.4166
Right anterosuperior: (n=3, 3, 3)-16.127 ± 13.9820-9.803 ± 3.3661-8.647 ± 10.1658

Adverse events

Collected over Treatment-emergent AEs will be defined as any AEs, regardless of relationship to study drug, that occur or worsen after the first dose of double-blinded study drug and no more than 30 days after the last dose of study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast + Pioglitazone—0/7 (0%)5/7 (71.4%)
Roflumilast Only—0/7 (0%)4/7 (57.1%)
Pioglitazone Only—0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventRoflumilast + PioglitazoneRoflumilast OnlyPioglitazone Only
Liver function test abnormalInvestigations0/70/72/6
HeadacheNervous system disorders1/72/72/6
DiarrhoeaGastrointestinal disorders2/71/71/6
NauseaGastrointestinal disorders1/72/70/6
Pain in extremityMusculoskeletal and connective tissue disorders2/70/70/6
EructationGastrointestinal disorders0/70/71/6
ChillsGeneral disorders0/70/71/6
FatigueGeneral disorders0/70/71/6
PyrexiaGeneral disorders0/70/71/6
InfluenzaInfections and infestations1/71/71/6

Baseline characteristics

The randomized set included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
Mean45.4 ± 9.6443.9 ± 14.7742.5 ± 8.6744.0 ± 10.93
Age, Customized
Age, Customized(participants)Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
18 - 39 years3238
40 - 59 years44311
60 - 80 years0101
Gender
Gender(Participants)Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
Female5229
Male25411
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
Hispanic or Latino0314
Non-Hispanic or Latino74516
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
Asian0202
White74617
Multiracial0101
Region of Enrollment
Region of Enrollment(participants)Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
United States77620
Height
Height(centimeter (cm))Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
Mean165.6 ± 15.13168.7 ± 8.62174.3 ± 7.50169.3 ± 11.13
Weight
Weight(kilogram (kg))Roflumilast + PioglitazoneRoflumilast OnlyPioglitazone OnlyTotal
Mean102.19 ± 21.04192.06 ± 20.784110.15 ± 15.456101.03 ± 19.887

3 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Coronado, California 92118, United States
  • Coronado, California, United States
  • Annapolis, Maryland 21401, United States
  • Baltimore, Maryland 21202, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2012
First posted
Oct 10, 2012
Start
Jun 2013
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Feb 23, 2016
Last update
Feb 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01703260
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 10, 2012
Start date
Jun 2013
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Feb 23, 2016
Last update
Feb 1, 2017

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roflumilast · Pioglitazone

Start the discussion